Recombinant Marburg viruses containing mutations in the IID region of VP35 prevent inhibition of Host immune responses*

César G. Albariño, Lisa Wiggleton Guerrero, Jessica R. Spengler, Luke S. Uebelhoer, Ayan K. Chakrabarti, Stuart T. Nichol, and Jonathan S. Towner

Centers for Disease Control and Prevention, Atlanta, USA

Abstract

Previous in vitro studies have demonstrated that Ebola and Marburg virus (EBOV and MARV) VP35 antagonize the host cell immune response. Moreover, specific mutations in the IFN inhibitory domain (IID) of EBOV and MARV VP35 that abrogate their interaction with virus-derived dsRNA, lack the ability to inhibit the host immune response. To investigate the role of MARV VP35 in the context of infectious virus, we used our reverse genetics system to generate two recombinant MARVs carrying specific mutations in the IID region of VP35. Our data show that wild-type and mutant viruses grow to similar titers in interferon deficient cells, but exhibit attenuated growth in interferon-competent cells. Furthermore, in contrast to wild-type virus, both MARV mutants were unable to inhibit expression of various antiviral genes. The MARV VP35 mutants exhibit similar phenotypes to those previously described for EBOV, suggesting the existence of a shared immune-modulatory strategy between filoviruses.

Keywords

Filovirus; Marburg virus; Bat virus; VP35; IFN-antagonism; Central basic; Patch; Immune-modulatory; Ebola virus

Introduction

Filoviruses (order Mononegavirales) are enveloped viruses with a single-strand RNA genome of negative-sense polarity (Feldmann et al., 2013). The viral genome is approximately 19 kb and encodes 7 genes: NP, VP35, VP40, GP, VP30, VP24, and L. These genes are separated by 6 intragenic untranslated regions and transcribed in sequential order from the 3′ to the 5′ end of the viral genome (Fig. 1A). Several viruses of the Filoviridae family, such as Ebola (EBOV), Sudan, Bundibugyo, Marburg (MARV), and Ravn viruses, cause sporadic outbreaks of viral hemorrhagic fevers (VHF) in sub-Saharan Africa with high case fatality rates (Albarino et al., 2013a; Hartman et al., 2010; Leroy et al., 2011). Three other filoviruses, Tai Forest virus, Reston virus, and Lloviu virus, have not caused

*The findings and conclusions in this report are ours and do not necessarily represent the views of the Centers for Disease Control and Prevention.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

*Corresponding author. jit8@cdc.gov (J.S. Towner).
known human fatalities to date (Feldmann et al., 2013; Leroy et al., 2011; Negredo et al., 2011).

A critical component of filovirus replication is the ability of virus-encoded proteins, such as the well-studied VP35 protein, to modulate the host immune response [see review in (Ramanan et al., 2011) and Fig. 1B]. The VP35 protein from EBOV and MARV, has been shown in protein expression studies to inhibit production of IFNβ by binding to dsRNA through a central basic patch (CBP) in the IFN inhibitory domains (IID), and block recognition of pathogen associated molecular patterns (PAMPs) by retinoic-acid inducible gene I (RIG-I)-like receptor (RLR) pathways (Bale et al., 2012; Bale et al., 2013; Leung et al., 2009; Leung et al., 2010; Ramanan et al., 2011; Zinzula et al., 2012). EBOV VP35 also inhibits the induction of RIG-I by PACT (Luthra et al., 2013) and dampens RIG-I signaling by interacting with the TBK-1/IKKe kinase and inhibiting IRF-3/7 phosphorylation (Cardenas et al., 2006; Hartman et al., 2006; Hartman et al., 2004; Prins et al., 2009). Moreover, EBOV VP35 was also shown to inhibit RNA silencing by interacting with two dsRNA-binding proteins, TRBP and PACT (Fabozzi et al., 2011; Zhu et al., 2012). In accordance with these findings, recombinant EBOV carrying specific mutations in the CBP region of VP35 showed an attenuated phenotype in mice and guinea pigs (Hartman et al., 2008; Prins et al., 2010a). In addition other filovirus proteins, such as VP24 and sGP from EBOV, and VP40 from MARV and Reston virus (Fig.1B) inhibit the host immune response by different mechanisms (Basler et al., 2004; Mateo et al., 2011; Mateo et al., 2010; Mohan et al., 2012; Reid et al., 2006; Reid et al., 2007; Valmas and Basler, 2011; Valmas et al., 2010).

In this report, we investigated the immune modulatory function of VP35 in MARV replication by engineering specific lesions designed to abrogate dsRNA PAMP recognition, and measure the effects of these mutations in the context of infectious virus. The mutant MARVs were generated using a recently developed reverse genetics system (Albarino et al., 2013b) derived from a MARV bat isolate and their phenotype and characterized in interferon-competent cells.

Results and discussion

To characterize relative MARV VP35 immune modulatory activities in our system, we compared the abilities of EBOV VP35 and MARV VP35, VP24, and VP40 to inhibit IFNβ production induced by Sendai virus (SeV). For this purpose, HEK-293 T cells were co-transfected with Pol II expression plasmids encoding each of the viral proteins (EBOV-VP35, MARV-VP35, MARV-VP24, or MARV-VP40), an IFNβ promoter-driven firefly luciferase (FLuc) reporter plasmid, and a Renilla luciferase (RLuc) transfection control plasmid. 24 h post-transfection (hpt), cells were induced by SeV infection, and luciferase activity was measured one day post infection (dpi). As shown in Fig. 1C, MARV VP35 inhibits IFNβ promoter activity to a greater extent than either MARV VP24 or VP40, while EBOV VP35 showed the most robust effect, as previously reported (Bale et al., 2012). Our results with MARV VP40 on the IFNβ promoter are consistent with those previously described for this protein (Valmas and Basler, 2011; Valmas et al., 2010) while the effect of MARV VP24 is consistent with the well characterized role of EBOV VP24 as an IFN
antagonist (Mateo et al., 2011; Mateo et al., 2010; Reid et al., 2006; Reid et al., 2007). Although a direct role as IFN antagonist has not been reported for MARV VP24, two recent reports describe an association of this protein with the interference of the inflammatory response (Edwards et al., 2014; Page et al., 2014). As shown in Fig. 2A and by others (Bale et al., 2012; Hartman et al., 2004; Prins et al., 2010b; Ramanan et al., 2012), the IFN inhibitory domain (IID) located in the C-terminal region of VP35 is strongly conserved among filoviruses. Previous reports showed that mutations in R312 of EBOV VP35, and in the equivalent position of MARV VP35 (R301), abrogate RNA binding and IFN suppression. In contrast, mutations in R305 of EBOV VP35 or R294 in MARV VP35 only moderately suppress these abilities (Bale et al., 2012; Bale et al., 2013; Hartman et al., 2006; Hartman et al., 2004; Leung et al., 2009; Leung et al., 2010; Ramanan et al., 2012). Moreover, recombinant EBOV with mutations in R305 and R312 of VP35 exhibited different in vitro and in vivo phenotypes when compared to WT virus (Hartman et al., 2008; Hartman et al., 2006).

In order to further characterize the immune modulatory activity of MARV VP35, we introduced two specific amino acids changes, R294A and R301A, into the WT expression plasmid, and tested the activity of the IFNβ promoter-driven FLuc as described above. As shown in Fig. 2B, WT MARV VP35 exhibits the most robust inhibition of IFNβ promoter activity. Both mutated forms of VP35 were less effective, particularly R301A. To confirm that the observed phenotypes were due to the introduced mutations and not differences in expression levels, we used Western blot analysis to quantify the amounts of WT and mutated forms of VP35 produced in transfected cells. When compared to actin levels, there are no substantial changes in R294A and R301A protein expression levels that could be linked to the decreased ability to inhibit the IFNβ promoter (Fig. 2C).

Based on the pronounced inhibitory effect of MARV VP35 on IFNβ production in human 293 T cells compared to the other MARV proteins (Fig. 1C), we wanted to further characterize the role of VP35 in dampening host cell PAMP recognition in the context of MARV infection. Before attempting the rescue of VP35 mutant MARV, we wanted to confirm that R294A and R301A mutations in VP35 would have deleterious effects on the MARV minigenome system. To do so, WT and mutant MARV VP35 expression plasmids were co-transfected with MARV NP, VP30, and L plasmids, along with the MARV minigenome expressing Gaussia Luciferase (gLuc) (Uebelhoer et al., 2014). Consistent with previous reports for EBOV VP35 (Hartman et al., 2006), the MARV VP35 mutations had no deleterious effects on the minigenome activity (Fig. 2D).

Using the MARV reverse genetics system (Albarino et al., 2013b; Uebelhoer et al., 2014), we generated WT recombinant MARV (rMARV) and two mutant viruses, rMARV-294 and rMARV-301, carrying R294A or R301A amino acid changes in VP35 respectively (Fig. 3A). Co-transfection of transcription plasmids containing the full-length genomes and support plasmids allowed the rescue of recombinant viruses in BHK cells. Viral stocks were further propagated by two passages in Vero-E6 cells, and growth kinetics were examined in Vero-E6 cells. As shown in Fig. 3B, rMARV, rMARV294, and rMARV-301 all exhibited similar growth kinetics in Vero-E6 cells, supporting our minigenome findings that, similar to EBOV, these mutations do not deleteriously affect the function of VP35 in MARV RNA replication.
To examine the immune modulatory role of VP35, we used rMARV, rMARV-294, and rMARV-301 to infect HEK-293 T cells stably transfected with an IFNβ promoter-driven FLuc reporter plasmid (293 T-IFNβ-FF). Infected cells were lysed 3 dpi, and luciferase activity was measured. Mock and rMARV-infected cells showed comparable levels of luciferase activity in (Fig. 3C). In contrast, cells infected with rMARV-294 showed slightly higher IFNβ promoter-driven FLuc activity, while those infected with rMARV-301 showed the highest relative FLuc activity. These results suggest that rMARV-294 and rMARV-301 viruses differ in their ability to modulate IFNβ activity.

We next compared the growth kinetics of WT and mutant rMARV in three different immuno-competent cell lines: Huh7 and A549 human-derived cell lines, and CD14+ macrophages, a primary target of viral replication during the course of primate infections. As shown in Fig. 4A, WT and mutant viruses exhibited similar growth kinetics in Huh7. In contrast, WT rMARV had a slight growth advantage over the mutant viruses in A549 cells and a 1–2 log advantage in CD14+ human macrophages. The different phenotypes of these recombinant viruses are consistent with previous reports of EBOV carrying the equivalent mutations in VP35 when tested in immune-competent cells, such as human macrophages (Hartman et al., 2006).

We suspect that the reduced growth of mutant viruses in CD14+ macrophages is due to their impaired ability to control the innate antiviral response during the course of infection. In order to test this hypothesis, we infected CD14+ macrophages with WT and mutant viruses and analyzed the expression of selected genes involved in the innate antiviral response. As shown in Fig. 4B, nearly all of the antiviral genes tested were over-expressed in macrophages infected by the mutants compared to those infected by WT virus. Infection by MARV-301 caused the greatest induction of innate immune genes and was also the mutant that was the most attenuated in CD14+ macrophages, thereby linking attenuated growth to the inability to antagonize innate immune responses. Consistent with this hypothesis, we found Huh7 and A549 cells to exhibit very minor changes in the expression level of these same antiviral genes (data not shown), when infected with wild-type or mutant viruses.

**Conclusions**

In this report we describe the successful generation of bat-derived recombinant MARV carrying mutations in VP35. Using these mutant MARVs, we demonstrated the ability of MARV VP35 to modulate expression of host immune response genes during infection of immune-competent cells. These mutant viruses lack the ability to suppress the innate antiviral response, resulting in high expression levels of several critical antiviral genes that correlate with impaired growth in human macrophages. Based on comparison to the growth phenotypes of analogous EBOV VP35 mutants with defects in dsRNA PAMP recognition (Hartman et al., 2006), these data suggest shared immune-modulatory strategies between genera within the family Filoviridae. It should be noted that MARV VP35, VP40, and VP24 likely function together as immune modulators. Indeed, the role of VP40 has been well characterized for MARV (Valmas and Basler, 2011; Valmas et al., 2010), while the role of VP24 as an IFN antagonist has been only reported for EBOV (Edwards et al., 2014; Mateo
et al., 2011; Mateo et al., 2010; Page et al., 2014; Reid et al., 2006; Reid et al., 2007), and will warrant further investigation.

**Materials and methods**

**Cell culture and biosafety**

All work with WT or recombinant MARV was performed in a biosafety level 4 (BSL-4) facility. BSR-T7/5, BHK21, and Vero-E6 cells were propagated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum (FBS) and penicillin-streptomycin (Pen-Strep), as recommended by the manufacturer (Invitrogen). BSR-T7/5 cells were a generous gift from K. Conzelmann (Buchholz et al., 1999). CD14+ macrophages were purified and seeded as previously described (Albarino et al., 2013b; McElroy and Nichol, 2012).

**Plasmid construction**

The construction of support plasmids, gLuc minigenome, and full-length clones corresponding to the full-length genome of 371Bat MARV (GenBank FJ750958) has been described before (Albarino et al., 2013b; Uebelhoer et al., 2014). Complete details on the construction of support expression plasmids and plasmids encoding a full-length clone carrying mutations in the C-terminal region of VP35 are available upon request. Briefly, the CGC codon at position 3,824 and the CGG codon at position 3,845 were changed to GCA in order to introduce the R294A and R301A amino acid changes in the VP35 protein.

**Minigenome expression**

A ~75% confluent monolayer of BSR-T7/5 cells grown in 12-well plates was transfected with 1.5 µg of MARV gLuc minigenome plasmid, 0.5 µg pC-L, 0.5 µg pC-NP, 0.05 µg pC-VP30, and 0.05 µg pC-VP35 WT or mutant plasmids. Plasmid pC-L was replaced by empty pCAGGS in the control. Aliquots of 5–10 µL of supernatant were collected 2–4 days post-transfection (dpt) to measure gLuc activity, as described before (Uebelhoer et al., 2014).

**Rescue of infectious viruses**

Rescue of recombinant viruses was performed in BHK21 cells as described previously (Albarino et al., 2013b). Briefly, a ~70% confluent monolayer of BHK21 cells grown in 12-well plates was transfected with 1.5 µg pMARV (expressing the full-length MARV genome in viral-complementary sense), 0.5 µg pC-L, 0.5 µg pC-NP, 0.05 µg pC-VP35, 0.05 µg pC-VP30, and 0.5 µg of pC-T7. Supernatants from the transfected cells were harvested 4 dpt, clarified by low-speed centrifugation, and passaged twice in Vero-E6 cells. The rescued viruses were sequenced to completion and no unexpected changes were noted. The complete sequence of recombinant wild-type and mutant viruses were deposited in GenBank (KP117261, KP117260, KP117259).

**Virus titration and growth curves**

To characterize the growth kinetics of recombinant viruses, $2 \times 10^6$ Huh7 and A549 cells, or $1 \times 10^5$ CD14+ macrophages were infected with WT or mutant viruses at multiplicity of
infection (moi) of 0.02. Virus was allowed to adsorb for 1 h with gentle rocking. After adsorption, monolayers were washed three times with PBS to eliminate any residual virus. Aliquots of 200 µL of the supernatant were taken daily, and viral titers were obtained by a tissue culture infective dose 50 (TCID₅₀) assay, as described before (Uebelhoer et al., 2014).

**IFNβ promoter assay in SeV infected cells**

Subconfluent monolayers of HEK-293 cells were co-transfected with pCAGGS plasmids encoding various viral proteins, the p125-luc FLuc reporter plasmid, and a plasmid constitutively expressing the RLuc (pRL-TK). The IFNβ FLuc reporter plasmid p125-luc, kindly provided by T. Fujita (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan), expresses FLuc under the control of the murine IFN-β promoter region (Yoneyama et al., 1996). The pRL-TK plasmid (Promega) contains a Herpes simplex virus thymidine kinase (HSV TK) promoter-driven encoding RLuc, used to control for transfection efficiency. 24 hpt, cells were induced with 200 hemagglutinin (HA) units/mL of SeV. Infected cells were lysed 1 dpi, and luciferase activity was measured using the Dual-Luciferase reporter assay system according to the manufacturer's instructions (Promega). FLuc activity was normalized to the RLuc value for each individual sample, and the fold-induction values were obtained by comparing infected cells with uninfected cells. Experiments were done in triplicate, and values are expressed as percent (%) activity relative to empty vector control set at 100% induction ± SD.

**IFNβ promoter assay in MARV-infected cells**

293 T-IFNβ-FF cells (Baum and Garcia-Sastre, 2011), a kind gift from Adolfo García-Sastre (Icahn School of Medicine at Mount Sinai Hospital), were cultured in DMEM supplemented with 10% FBS, 1% L-glutamine, and 1% Pen-Strep. Cells were plated in low-serum media (2% FBS) to sub-confluent levels in 48-well plates, and infected with rMARV, rMARV-294, and rMARV-301 (moi=0.5). At 3 dpi, cells were lysed, and luciferase activity was measured using the LARII reagent component of the Dual-Luciferase reporter assay system, according to the manufacturer's instructions (Promega). Activity is expressed as average relative luciferase units (RLU) of 8 replicates ± SD.

**Gene expression array**

Sub-confluent monolayers of Huh7, A549 cells, or CD14+ selected human macrophages grown in 24-well plates were mock-infected or infected with rMARV, rMARV-294, or rMARV-301 (moi=2) in duplicate. 24 hpi, supernatants were removed, and cells were lysed for total RNA purification following previously described protocols (McMullan et al., 2012). 2 µg of total RNA was subjected to an extensive DNAse digestion following the manufacturer's protocol (RNasey, Qiagen), and subsequently used in a qRT-PCR reaction using SuperScript III Platinum SYBR Green One-Step qRT-PCR and following the manufacturer's protocol (Invitrogen). Gene expression profiles were obtained using a commercially available array (Antiviral Response PCR Array, Qiagen/SABiosciences).
Acknowledgments

We thank K. Conzelmann (Ludwig-Maximilians-University, Munich, Germany) for providing BSRT7/5 cells, A. García-Sastre (Icahn School of Medicine at Mount Sinai, New York, USA) for providing 293 T-IFNβ–FF cells, and T. Fujita, (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan) for providing the p125-luc reporter plasmid. We also thank Anita McElroy for technical support during macrophage purification, Marina L. Khristova for continuous excellent sequencing support, and Tatyana Klimova for editing of this work.

References

Albarino CG, Shoemaker T, Khristova ML, Wamala JF, Muyembe JJ, Balinandi S, Tumusiime A, Campbell S, Cannon D, Gibbons A, Bergeron E, Bird B, Dodd K, Spiropoulou C, Erickson BR, Guerrero L, Knust B, Nichol ST, Rollin PE, Stroher U. 2013a; Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. Virology. 442:97–100. [PubMed: 23711383]

Albarino CG, Uebelhoer LS, Vincent JP, Khristova ML, Chakrabarti AK, McElroy A, Nichol ST, Towner JS. 2013b; Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate. Virology. 446:230–237. [PubMed: 24074586]

Bale S, Julien JP, Bornholdt ZA, Kimberlin CR, Halfmann P, Zandonatti MA, Kunert J, Kroon GJ, Kawaoka Y, MacRae JJ, Wilson IA, Saphire EO. 2012; Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog. 8:e1002916. [PubMed: 23028316]

Bale S, Julien JP, Bornholdt ZA, Krois AS, Wilson IA, Saphire EO. 2013; Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism. J. Virol. 87:10385–10388. [PubMed: 23824825]

Basler M, Youhnovski N, Van Den Broek M, Przybylski M, Groettrup M. 2004; Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J. Immunol. 173:3925–3934. [PubMed: 15356141]

Baum A, Garcia-Sastre A. 2011; Differential recognition of viral RNA by RIG-I. Virulence. 2:166–169. [PubMed: 21422808]

Buchholz UJ, Finke S, Conzelmann KK. 1999; Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73:251–259. [PubMed: 9847328]

Cardenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martinez-Sobrido L, Saphire EO, Basler CF. 2006; Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80:5168–5178. [PubMed: 16698997]

Edwards MR, Johnson B, Mire CE, Xu W, Shabman RS, Speller LN, Leung DW, Geisbert TW, Amarasinghe GK, Basler CF. 2014; The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell Rep. 6:1017–1025. [PubMed: 24630991]

Fabozzi G, Nabel GS, Dolan MA, Sullivan NJ. 2011; Ebola virus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J. Virol. 85:2512–2523. [PubMed: 21228243]

Feldmann, H, Sanchez, A, Geisbert, TW. Filoviridae: Marburg and Ebola viruses. In: Knipe, DMa; PM, H, editors. Fields Virology. Sixth. Lippincott, Williams and Wilkins; Philadelphia: 2013. 923–956.

Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, Nichol ST. 2008; Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J. Virol. 82:2699–2704. [PubMed: 18199658]

Hartman AL, Dover JE, Towner JS, Nichol ST. 2006; Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 80:6430–6440. [PubMed: 16775331]
Hartman AL, Towner JS, Nichol ST. 2004; A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology. 328:177–184. [PubMed: 15464838]

Hartman AL, Towner JS, Nichol ST. 2010; Ebola and marburg hemorrhagic fever. Clin. Lab. Med. 30:161–177. [PubMed: 20513546]

Leroy EM, Gonzalez JP, Baize S. 2011; Ebola and Marburg hemorrhagic viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin. Microbiol. Infec.: Off. Publ. Eur. Soc. Clin. Microbiol. Infec. Dis. 17:964–976.

Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, Amarasinghe GK. 2009; Structure of the Ebola VP35 interferon inhibitory domain. P. Natl. Acad. Sci. USA. 106:411–416.

Leung DW, Prins KC, Borek DM, Farahbaksh M, Tufario JM, Ramanan P, Nix JC, Helgeson LA, Otwonowski Z, Honzatko RB, Basler CF, Amarasinghe GK. 2010; Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 17:165–172. [PubMed: 20081868]

Luthra P, Ramanan P, Mire CE, Weisend C, Tsuda Y, Yen B, Liu G, Leung DW, Geisbert TW, Ebihara H, Amarasinghe GK, Basler CF. 2013; Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe. 14:74–84. [PubMed: 23870315]

Mateo M, Carbonnelle C, Reynard O, Kolesnikova L, Nemirov K, Page A, Volchkova VA, Volchkov VE. 2011; VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. J. Infect. Dis. 204(Suppl 3):S1011–S1020. [PubMed: 21987737]

Mateo M, Reid SP, Leung LW, Basler CF, Volchkov VE. 2010; Ebola virus VP24 binding to karyopherins is required for inhibition of interferon signaling. J. Virol. 84:1169–1175. [PubMed: 19899762]

McElroy AK, Nichol ST. 2012; Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology. 422:6–12. [PubMed: 22018491]

McMullan LK, Frace M, Sammons SA, Shoemaker T, Balinandi S, Wamala JF, Lutwama JJ, Downing RG, Stroehler U, MacNeil A, Nichol ST. 2012; Using next generation sequencing to identify yellow fever virus in Uganda. Virology. 422:1–5. [PubMed: 21962764]

Mohan GS, Li W, Ye L, Compans RW, Yang C. 2012; Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog. 8:e1003065. [PubMed: 23271969]

Negredo A, Palacios G, Vazquez-Moron S, Gonzalez F, Dopazo H, Molero F, Juste J, Quetglas J, Savji N, de la Cruz Martinez M, Herrera JE, Pizarro M, Hutchison SK, Echevarria JE, Lipkin WI, Tenorio A. 2011; Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog. 7:e1002304. [PubMed: 22039362]

Page A, Volchkova VA, Reid SP, Mateo M, Bagnaud-Baule A, Nemirov K, Shurtleff AC, Lawrence P, Reynard O, Ottmann M, Lotteau V, Biswal SS, Thimmulappa RK, Bavari S, Volchkov VE. 2014; Marburgvirus hijacks nrf2dependent pathway by targeting nrf2-negative regulator keap1. Cell Rep. 6:1026–1036. [PubMed: 24630992]

Prins KC, Binning JM, Shabman RS, Leung DW, Amarasinghe GK, Basler CF. 2010a; Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J. Virol. 84:10581–10591. [PubMed: 20686031]

Prins KC, Cardenas WB, Basler CF. 2009; Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 83:3069–3077. [PubMed: 19153231]

Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, Ramanan P, Cardenas WB, Amarasinghe GK, Volchkov VE, Basler CF. 2010b; Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 84:3004–3015. [PubMed: 20071589]
Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek DM, Otwinowski Z, Liu G, Huh J, Basler CF, Amarasinghe GK. 2012; Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. P. Natl. Acad. Sci. USA. 109:20661–20666.

Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. 2011; Filoviral immune evasion mechanisms. Viruses. 3:1634–1649. [PubMed: 21994800]

Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. 2006; Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80:5156–5167. [PubMed: 16698996]

Reid SP, Valmas C, Martinez O, Sanchez FM, Basler CF. 2007; Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 81:13469–13477. [PubMed: 17928350]

Uebelhoer LS, Albarino CG, McMullan LK, Chakrabarti AK, Vincent JP, Nichol ST, Towner JS. 2014; High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antivir. Res. 106:86–94. [PubMed: 24713118]

Valmas C, Basler CF. 2011; Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J. Virol. 85:4309–4317. [PubMed: 21325424]

Valmas C, Grosch MN, Schumann M, Olejnik J, Martinez O, Best SM, Krahling V, Basler CF, Muhlberger E. 2010; Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog. 6:e1000721. [PubMed: 20084112]

Yoneyama M, Suhara W, Fukuhara Y, Sato M, Ozato K, Fujita T. 1996; Autocrine amplification of type I interferon gene expression mediated by interferon stimulated gene factor 3 (ISGF3). J. Biochem. 120:160–169. [PubMed: 8864859]

Zhu Y, Cherukuri NC, Jackel JN, Wu Z, Crary M, Buckley KJ, Bisaro DM, Parris DS. 2012; Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cells. J. Virol. 86:3038–3049. [PubMed: 22238300]

Zinzula L, Esposito F, Pala D, Tramontano E. 2012; dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35. Antivir. Res. 93:354–363. [PubMed: 22289166]
Fig. 1.
(A) Basic organization of the MARV genome. The 7 ORFs are depicted in the viral complementary sense (5′ to 3′). (B) Filovirus proteins involved in immune evasion. The immune modulator functions of filovirus proteins are divided into three broad classes; citations are included. (C) IFNβ promoter assay in SeV infected cells. HEK-293 cells were co-transfected with expression plasmids encoding EBOV VP35, MARV VP35, MARV VP24, or MARV VP40, along with p125-luc reporter plasmid expressing firefly luciferase (FLuc), and pRL-TK control plasmid expressing Renilla luciferase (RLuc). Cells were infected with SeV 24 hpt, and luciferase activity was measured 1 dpi. FLuc activity was
normalized to RLuc, and the fold-increase in induction was determined by comparing infected cells with uninfected cells.
Fig. 2.
(A) Sequence conservation in central basic patch (CBP) of filovirus VP35 IFN-inhibiting domain (IID). Partial amino acid sequences were aligned to show the conservation of IID. The two amino acid residues modified in EBOV in a previous report (Hartman et al. 2006), and in MARV in this current report are indicated with arrows. VP35 sequences were derived from accession numbers AF086833, NC_004161, FJ217162, NC_014373, NC_006432, DQ447649, NC_001608, and FJ750958. (B) IFNβ promoter assay. HEK-293 cells were co-transfected with expression plasmids encoding WT MARV VP35, or the mutant proteins VP35-294 or VP35-301. Cells were infected with SeV 24 hpt, and luciferase activity was...
measured as described in Fig.1C. (C) Expression of WT and mutant VP35. HEK-293 cells were transfected as described above, and protein lysates were immunostained with antibodies against MARV (upper panel) or actin (lower panel). (D) Minigenome replication. Schematic of MARV Luc minigenome system. The structure of plasmids coding the minigenome (Uebelhoer et al., 2014) is shown with 371Bat 5’ and 3’ untranslated regions (black line), and support plasmids expressing viral proteins (dashed line indicates pCAGGS plasmid sequence). Amino acid substitutions to alanine in VP35 are indicated for pC-VP35-294 and pC-VP35-301 expression plasmids. To assess minigenome replication BSR-T7/5 cells co-transfected with plasmids encoding the MARV mini-genome and with support plasmids expressing viral proteins pC-NP, pC-VP35, pC-VP30, and pC-L. In the indicated lanes, pCVP35 was swapped for pC-VP35-294, pC-VP35-301, or pC-L was swapped for pCAGGS as a no polymerase control. Data are representative of three independent experiments, with mean and standard error of the mean (SEM) of luciferase expression from three wells displayed for each time point in relative light units (RLUs). (B).
Fig. 3.
Rescue and characterization of recombinant WT and mutant MARV viruses. (A) Schematic representation of recombinant MARV genomes. Full-length MARV complementary genome is depicted with the amino acid substitutions in VP35 indicated for rMARV-294 and rMARV-301 mutants viruses. WT and mutant recombinant viruses were rescued in BHK-21 cells and passaged twice in Vero-E6 cells as described before (Albarino et al., 2013b). (B) Growth kinetics in Vero-E6 cells. Cells were infected with rMARV, rMARV-294, or rMARV-301 mutants viruses (moi=0.02). After 1 h adsorption followed by three PBS washes, supernatants viruses were collected at the indicated time points. Viral titers were measured
by tissue culture infective dose 50 (TCID₅₀) in Vero-E6 cells as described before (Uebelhoer et al. 2014). (C) IFN-β promoter assay in MARV infected cells. HEK-293 cells stably transfected with an IFN-β promoter-driven FLuc reporter plasmid (293 T-IFNβ-FF) were infected with rMARV, rMARV-294, or rMARV-301. Cells were lysed 3 dpi, and luciferase activity was measured.
Fig. 4.
A. Growth kinetics of WT and VP35 mutants in IFN-competent cells. Huh7, A549 and human macrophages were infected with WT rMARV, rMARV-294, or rMARV-301, and viral titers were determined by TCID$_{50}$ assay in Vero-E6 cells. Substantial changes in growth kinetics were noticed only in CD14+ macrophages. B. Expression of antiviral genes in cells infected with WT or mutant MARV. Selected genes corresponding to four groups associated with different receptors and their signaling pathways (type-I IFN, Nod-like receptor, toll-like receptor, and RIG-I-like receptor) with important fold regulation values (cut-off= 10) are shown.